Patent · US Active

PCSK9 antibody, antigen-binding fragment thereof, and medical application thereof

US10793643B2 · kind B2 · utility

0Cited by

10References

24Claims

0Family size

Assignees

Inventors

Xiangdong QU · Shanghai, CN
Xin Ye · Beijing, CN
Shaoyu Xu · Ningbo City, CN
Bei Yuan · Shanghai, CN
Dongbing Cui · Shanghai, CN
Qiyue Hu · Shanghai, CN
Lei Zhang · Beijing, CN
Zhibin Xu · Shanghai, CN
Weikang Tao · Shanghai, CN
Lianshan Zhang · 安丰镇, CN
Piaoyang Sun · Lianyungang, CN

Key dates

Filing date	Dec 20, 2016
Grant date	Oct 6, 2020
Priority date	—
Expiry date	Aug 18, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention provides a PCSK9 antibody, an antigen-binding fragment thereof, and a medicinal application thereof. Provided in the invention is a chimeric antibody and a humanized antibody, both comprising a CDR of the PCSK9 antibody, and a pharmaceutical composition comprising the PCSK9 antibody and an antigen-binding fragment thereof, and an application of the PCSK9 antibody as a lipid-lowering agent. The invention specifically relates to an application of a humanized PCSK9 antibody for preparing a pharmaceutical drug to treat a PCSK9-induced disease or symptom.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.